Tahoe (formerly Vevo) Featured in Michael Einstein's Nature Biotechnology Article

Finding and optimizing drugs in rudimentary in vitro assays is like “finding the best sprinter and sending them to run a marathon”.

As Michael outlines in his article Biotechs take multiplexing into animal models to accelerate drug discovery, we at Tahoe Therapeutics (formerly Vevo) believe that the root of many failures in the clinic is how we model disease preclinically. We need better disease models that capture the fact that disease happens in a living organism and in extremely heterogeneous patients that can not be reduced to a single driver gene or protein target. Disease models that can capture this at scale will not only lead to better therapeutics but also unlock new business models that can change the economics of drug discovery.